NASDAQ: MGX
Metagenomi Therapeutics Inc Earnings Dates, Reports, Calls

Metagenomi Therapeutics earnings were -$85.9M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MGX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$23.1M, up 2.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MGX reported annual earnings of -$87.9M, with 12.6% growth.

MGX earnings history

Current Revenue
$22.3M
Current Earnings
-$85.9M
Current Profit Margin
-384.6%

MGX Return on Equity

Current Company
-51.2%
Current Industry
-142.1%
Current Market
14.1%
MGX's Return on Equity (-51.2%)... subscribe to Premium to read more.
High Return on Equity Performance

MGX Return on Assets

Current Company
-36.6%
Current Industry
-13.5%
MGX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MGX announces earnings.

MGX Return on Capital Employed

Current Company
-49.32%
Current Industry
-9.4%

MGX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MGX-$75.42M-$85.89MN/A-$2.30
ATYR-$68.47M-$70.03MN/A-$0.73
XLO-$29.91M-$31.30MN/A-$2.55
GNTA-$7.47M-$7.51MN/A-$0.38
GOSS-$168.59M-$180.40MN/A-$0.79

Metagenomi Therapeutics Earnings Reports & History FAQ

What were Metagenomi Therapeutics's earnings last quarter?

On MGX's earnings call on Invalid Date, Metagenomi Therapeutics (NASDAQ: MGX) reported Q1 2026 earnings per share (EPS) of -$0.61, up 10.29% year over year. Total MGX earnings for the quarter were -$23.06 million. In the same quarter last year, Metagenomi Therapeutics's earnings per share (EPS) was -$0.68.

If you're new to stock investing, here's how to buy Metagenomi Therapeutics stock.

Is Metagenomi Therapeutics profitable or losing money?

As of the last Metagenomi Therapeutics earnings report, Metagenomi Therapeutics is currently losing money. Metagenomi Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$85.89 million, a 10.18% increase year over year.

What was MGX's earnings growth in the past year?

As of Metagenomi Therapeutics's earnings date in Invalid Date, Metagenomi Therapeutics's earnings has grown year over year. MGX earnings in the past year totalled -$85.89 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.